HEALTHSENS NEPHROPOC® is an in vitro diagnostic medical device (IVD-MD) designed to quantify CREATININE levels in peripheral blood and calculate the estimated glomerular filtration rate (eGFR). In this way, it is possible to have total control over renal disease, which is considered the third disease of impact worldwide and affects 10% of the population.
HEALTHSENS NEPHROPOC® is a self-diagnostic medical device authorized to be used by the patient.
HEALTHSENS NEPHROPOC®allows the early diagnosis and monitoring of kidney disease, as well as other multisystemic pathologies by determining creatinine and calculating eGFR.
CREATININE is the biomarker par excellence associated with kidney disease, so its levels should be controlled frequently.
HEALTHSENS NEPHROPOC® technology is robust, portable, low cost and easy to use, and shows great reliability for early diagnosis and monitoring of kidney disease. It allows the patient to be autonomous in the management of his disease, providing security at all times.
Its analytical characteristics reflect the good results obtained in total blood measurements, showing high accuracy when compared with other methods used in clinical practice.
Features of the Self-diagnostic Device
- Analysis time: 40 seconds.
- Sample size: a small drop of peripheral blood obtained by puncture on a finger.
- Measuring range: between 0.9 and 15.0 mg/dL.
- Connectivity: Bluetooth.
- Weight: 58.67 grams.
- Dimensions: 95 mm (length) x 48 mm (width) x 20 mm (height).
- Healthsens Nephropoc® Can be purchased in Spain on prescription in other countries consult the current health legislation of each territory.
The accuracy of our method has been analyzed by comparison with the reference method, based on isotope dilution by mass spectrometry (IDMS), and the method most used in clinical practice for quantifying CREATININE (Cobas 8000 c 7012, based on Jaffé’s reaction).
La especificidad se ha evaluado teniendo en cuenta las posibles interferencias que puedan afectar a la medida de creatinina. Se ha comprobado que no existen interferencias para compuestos como acetaminofeno, ácido ascórbico, bilirrubina, creatina, dopamina, glucosa, heparina, levodopa o sarcosina.
Chronic kidney disease affects 10% of the world’s population.
986,246 deaths directly related to chronic kidney disease in 2013.
A 134% increase in deaths due to chronic kidney disease
96% of people with kidney damage or slightly reduced kidney function are not aware of having Chronic Kidney Disease
Need more information? Contact us!
Please feel free to contact us for more information on HEALTHSENS.